Abstract. In this communication, the roles of apoptosisinducing factor (AIF) and Bcl-2 inhibitor of transcription (Bit1) in TAp63Á-induced apoptosis were investigated in human esophageal squamous cancer EC9706 cells. Positive RNA and protein expressions of AIF and Bit1 in these cells were verified. However, no TAp63Á could be detected. Transfection of expression vector pcDNA3.1-TAp63Á into EC9706 resulted in TAp63Á expression, and peak level apoptosis was observed 24 h after the transfection disclosed by DNA fragmentation assay. In addition, it was found with Western blot that AIF and Bit1 were released into cytosol from mitochondria, and AIF was further translocated into nucleus, during the stage of TAp63Á-induced cell apoptosis. Down-regulation of either AIF or Bit1 by RNA interference could, however, alleviate TAp63Á-induced cell apoptosis. In conclusion, TAp63Á could induce apoptosis in human esophageal squamous cancer EC9706 cells, through at least releasing AIF and Bit1 from mitochindria into cytosol and nucleus, where apoptotic cascade takes place. These findings indicate that mitochondria-released proapoptotic proteins, AIF and Bit1, are important factors in a TAp63Á-induced EC9706 cell apoptosis pathway.
Introduction
p63 is a member of the p53 family (1, 2) . It contains regions of homology to p53 and shares 60% sequence identity with the DNA-binding domain, 22% identity with the N-terminal transactivation domain and 37% identity with the oligomerization domain of p53. In contrast to p53, however, human p63 has two promoters, which result in two different types of protein products with opposite functions: the full-length transcriptionally active TAp63 and the dominant-negative ΔNp63. Furthermore, p63 can vary at its carboxy-terminal end, as a result of alternative splicing at the 3' portion of the mRNA, which yields isoforms such as ·, ß and Á (3).
p63 shares some of p53 functions due to the strong structural similarity (3) . There is mounting evidence indicating that a large number of endogenous p53 target genes are transactivated by p63 to mediate cell cycle arrest and induce apoptosis, independently of p53 status (3) (4) (5) . In addition, Perp, which originally was identified as an apoptosisassociated target of the p53 tumor suppressor (6, 7) , is the direct target of p63 clearly involved in mediating developmental program in vivo (8, 9) . Recent evidence has revealed that cytoplasmic p53 directly activates Bcl-2 proteins to initiate apoptosis, but nuclear p53 regulates the expression of proapoptotic genes (10, 11) , such as the PUMA gene. In contrast, TAp63Á functions only in the nucleus showing strong proapoptotic ability (3) .
In stressed cells, the induction of cytosolic Bax protein expression may contribute to its activation, oligomerization and translocation to mitochondria, triggering loss of the mitochondrial membrane potential and the release of cyto-c and apoptosis-inducing factor (AIF) (8, 12, 13) . Despite the mechanisms involving p53 mediated apoptosis pathways, it is still suggested that at least some signaling pathways are utilized by other members of p53 family in the absence of p53 (14) .
AIF and Bcl-2 inhibitor of transcription (Bit1) are both mitochondrial proteins, and are recently identified caspaseindependent apoptosis effectors. AIF can translocate to the nucleus to execute chromatin condensation and apoptosis by a mechanism independent of caspases (15 (16) (17) (18) (19) (20) . Bit1, a proapoptotic protein whose cytoplasmic expression induces cell death, interacts with AES (a member of the Groucho family of transcriptional corepressors) to induce apoptosis (21) . This type of apoptosis is also called anoikis which means loss of cell attachment to the extracellular matrix to cause apoptosis (21) . However, cell attachment to fibronectin counteracts the apoptotic effect of Bit1, and overexpression of the antiapoptotic family member Bcl-2 or Bcl-xl prevents the release of Bit1. Staurosporine treatment results in the release of Bit1 into the cytosol (21) . Similarly, staurosporine also induces mitochondrial permeability and the release of AIF. However, the changes of mitochondrial permeability and the apoptotic targets activated by p63 remain to be discovered.
To clarify the role of molecular mechanism of TAp63 in apoptosis, we chose to investigate the correlation between TAp63 expression and the release of AIF and Bit1 from mitochondria in vitro, by introducing the TAp63Á expression vector into human esophageal squamous carcinoma EC9706 cells. TAp63Á was chosen in this study because it has been proved to be the most powerful transactivating TAp63 isoform (3).
Materials and methods

Cells, vectors, antibodies and reagents.
Human esophageal squamous carcinoma cell line (EC9706) was kindly provided by State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Science; pcDNA3.1, pcDNA3.1-TAp63Á, pcDNA3.1-p53 and pcDNA3.1/Myc-His-TAp63Á were kindly provided by Dr Yaohe Wang; chicken polyclonal IgY to CGI-147(Bit1) and HRP-linked affinity-purified rabbit anti-IgY were obtained from Genway; goat polyclonal IgG to AIF, mouse polyclonal to p53, rabbit polyclonal to ß-actin and HRP-linked antibodies were purchased from Santa Cruz; mouse monoclonal IgG 1 to his-tag was from Novagen. Rabbit polyclonal IgG to histone H 3 and voltage-dependent anion channel (VDAC) were bought, respectively, from Millipore and Rockland; RPMI-1640 medium was from Gibco; one step reverse transcriptase-polymerase chain reaction (RT-PCR) kit was from Takara; DNA Ladder kit, TdT-mediated dUTP nick-end labeling (TUNEL) apoptosis detection kit and Annexin V-FITC kit were from Beyotime Biotechnology, KeyGen Biotechnology and Beckman Coulter, respectively; mitochondrial/cytosol fractionation kits were purchased from BioVision; NE-PER nuclear and cytoplasmic extraction reagents were obtained from Pierce Biotechnology; TransIT-LT1 transfection reagent was purchased from Mirus; oligonucleotides and the primers were obtained from Shanghai Sangon Biological Engineering technology and service Co., Ltd.
Cell culture. EC9706 was cultured in RPMI-1640 medium containing 10% fetal bovine serum, 100 U/ml penicillin and streptomycin, in a humidified atmosphere of 5% CO 2 at 37˚C.
RNA preparation and RT-PCR.
Total RNA was prepared from the EC9706 cells with TRIzol reagent according to the manufacturer's protocol and treated with the DNA-free kit to remove residual genomic DNA. Briefly, the RNA isolated (1 μg) was used as template to perform one step RT-PCR according to the protocol and ß-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The following oligonucleotide primers were used for analysis of AES, Bit1, TAp63Á, TAp63 and ΔNp63 amplification. For AES (508 bp), forward 5'-GCGACCGCATCAAAGAC-3'; reverse 5'-TTCTCGCCATCATCCTCC-3'; for Bit1 (428 bp), forward 5'-ATGCCCTCCAAATCCTT-3'; reverse 5'-ATTAAACTTACAGTCAGTCCC-3'; for TAp63Á (1346 bp), forward 5'-ATGTCCCAGAGCACACAGAC-3'; reverse 5'-TATGGGTACACTGATCGGTT-3'; for ΔNp63 (335 bp), forward 5'-TGCCCAGACTCAATTTAGTGAG-3'; reverse 5'-TCTGGATGGGGCATGTCTTTGC-3'; for TAp63 (334 bp), forward 5'-GACCTGAGTGACCCCATGTG-3'; reverse 5'-TCTGGATGGGGCATGTCTTTGC-3'; for ß-actin (315 bp), forward, 5'-TCCTGTGGCATCCACGAAACT-3'; reverse 5'-GAAGCATTTGCGGTGGACGAT-3'; for GAPDH (915 bp), forward 5'-AAGGTCGGAGTCAACGGATTTG-3'; reverse 5'-CTTGACAAAGTGGTCGTTGAGG-3'. The amplified products were subjected to electrophoresis on 1% agarose gels.
TransIT-LT1 transfection. Approximately 24 h prior to transfection, cells were plated at a density of 2-6x10 5 cells in complete growth medium to obtain 50-70% confluence. The following day, 15 μl of TransIT-LT1 transfection reagent (2-8 μl/1 μg DNA) was directly added into 500 μl of serumfree medium and mixed completely by gentle pipetting and incubated at RT for 20 min. Then, 5 μg of plasmid DNA was added to the diluted TransIT-LT1 transfection reagent and mixed by gentle pipetting. The mixture was incubated at RT for 30 min. The medium was replaced with 3 ml of fresh complete growth medium per dish. Finally, the TransIT-LT1 reagent/DNA complex mixture was added to the dishes. The dishes were kept gently rocking for a few minutes in order to distribute the complex evenly, and incubated for 24 h. After that, cells were collected for the following experiments.
DNA fragmentation assay. Cells were transfected with pcDNA3.1, pcDNA3.1-TAp63Á and pcDNA3.1-p53 vectors, respectively and harvested at 6, 12, 24 and 48 h after the transfection. Cells were rinsed with PBS and incubated with lysate buffer containing protease K at 50˚C overnight. DNA fragments were purified by phenol-chloroform extraction and ethanol precipitation at -70˚C, and dissolved in 50 μl of TE. Purified DNA (3 μl) from each sample was loaded into 1% agarose gel, electrophoresed for 30 min at 75 volts and visualized under ultraviolet light after ethidium bromide staining.
TUNEL assay. Cells were transfected with pcDNA3.1 and pcDNA3.1-TAp63Á vectors and harvested at 24 h, respectively. After rinsing with PBS, 1x10 4 cells were plated on polylysinecoated slides. Air dried cell samples were fixed with a freshly prepared fixation solution for 1 h at 15-25˚C and then rinsed with PBS three times. After incubated with blocking solution for 10 min at 15-25˚C and rinsed with PBS three times, slides were incubated in permeabilisation solution for 2 min on ice.
The samples were rinsed twice with PBS and then kept dry. To each slide 50 μl TUNEL reaction mixture was added and incubated for 60 min at 37˚C in wet and dark atmosphere. Rinsed and kept dry with filter paper, 50 μl Streptavidin-HRP working solution was added and incubated for 30 min at 37˚C in wet and dark atmosphere. After rinsing and drying, 50 μl DAB substrate was added and incubated for 10 min at 15-25˚C. Finally, samples were rinsed three times and mounted under glass coverslip and analyzed with light microscope. Negative control (label solution contained no terminal deoxynucleotidyl transferase in TUNEL reaction mixture) and positive control (incubation of permeabilized cells with 100 μl DNAse 1 buffer for 10 min at 15-25˚C, prior to labeling procedures) were also performed.
Annexin V-FITC kit apoptosis assay. The cultured cells were harvested after the 24 h transfection, with pcDNA3.1 and pcDNA3.1-TAp63Á, respectively, washed with ice-cold PBS and centrifuged for 5 min at 500 x g at 4˚C. The supernatant was discarded, and the cell pellet was resuspended in ice-cold binding buffer. Annexin V-FITC solution (5 μl) and 2.5 μl of PI was added to 100 μl of the cell suspension and then kept on ice for 10 min-incubation in dark before 400 μl of ice-cold binding buffer was added to the preparation. The suspension was gently mixed before it was analyzed within 30 min by flow cytometry.
RNA interference (RNAi).
Hairpin oligonucleotides of AIF and Bit1 were respectively designed according to Yuan et al (22) and Jan et al (21) . For AIF, the sense sequence is 5'-GATC CGCTTGTTCCAGCGATGGCATTTCAAGAGAATGCC ATCGCTGGAACAAGTTTTTTGGAAA-3'; the antisense sequence is 5'-AGCTTTTCCAAAAAACTTGTTCCAGC GATGGCATTCTCTTGAAATGCCATCGCTGGAACAA GCG-3'. For Bit1, the sense sequence is 5'-GATCCGCTT GGTTATGGAATATTTGTTCAAGAGACAAATATTCC ATAACCAAGTTTTTTGGAAA-3'; the antisence sequence is 5'-AGCTTTTCCAAAAAACTTGGTTATGGAATATTT GTCTCTTGAACAAATATTCCATAACCAAGCG-3. For negative control, the sense sequence is 5'-GATCCGTTCTC CGAACGTGTCACGTTTCAAGAGAACGTGACACGTT CGGAGAATTTTTTGGAAA-3'; the antisense sequence is 5'-AGCTTTTCCAAAAAATTCTCCGAACGTGTCACGT TCTCTTGAAACGTGACACGTTCGGAGAACG-3'. The sense strand and anti-sense one were annealed to form hairpin small interfence RNA (siRNA) template insert. The annealed siRNA template was ligated with pSilencer3.1-H1-neo using T4 DNA ligase, transformed into competent Escherichia coli DH5· and amplified. Clones with the hairpin siRNA insert were identified by digesting isolated plasmid DNA with BamHI and HindIII and the inserted sequence was verified by sequencing. Then, pSilencer3.1-H1-neo containing the siRNA templates was transfected into EC9706 cells. After G418 selection, AIF and Bit1 protein expression in the experimental and control groups of EC9706 cells were analyzed with Western blot as described above.
Mitochondrial/cytosol fractionation. Twenty-four hours after transfection, respectively, with pcDNA3.1-TAp63Á, pcDNA3.1-p53 (positive control) and pcDNA3.1 (negative control), cells (5x10 7 ) were harvested and rinsed with ice-cold PBS, and then centrifuged at 600 x g for 5 min at 4˚C. The cells were resuspended with 1 ml of the cytosol extraction buffer mix containing DL-Dithiothreitol and protease inhibitors, incubated on ice for 10 min, and homogenized with an ice-cold tissue grinder on ice for 30-50 passages. The homogenate was transferred to a 1.5 ml microcentrifuge tube and centrifuged at 700 x g for 10 min at 4˚C. The supernatant was collected into a fresh 1.5 ml tube and centrifuged at 10,000 x g for 30 min at 4˚C. The supernatant was collected as cytosolic fraction, and the pellet was resuspend with 100 μl of mitochondrial extraction buffer mix containing DTT and protease inhibitors, and vortexed for 10 sec as mitochondrial fraction.
Nuclear protein extraction. Twenty-four hours after transfection, respectively, with pcDNA3.1-TAp63Á, pcDNA3.1-p53 (positive control) and pcDNA3.1 (negative control), cells (5x10 7 ) were harvested and rinsed with ice-cold PBS, and then centrifuged at 600 x g for 5 min at 4˚C. The cell pellet was resuspended with 200 μl of ice-cold CER I, vortexed and incubated on ice for 10 min before adding 11 μl of ice-cold CER I, then vortexed and incubated on ice for 1 min before it was centrifuged at 16,000 x g for 5 min at 4˚C. The sedimentation was resuspended with 50 μl of ice-cold NER, vortexed on the highest setting for 15 sec, kept on ice and vortexed for 15 sec every 10 min, for a total of 40 min before it was centrifuged at 16,000 x g for 10 min at 4˚C. The supernatant fractionation was immediately transferred to a clean pre-chilled tube and stored at -80˚C for use.
Western blot. Subcellular protein (50 μg) was added to 2x protein sample buffer, heated at 100˚C for 5 min and separated with sodium dodecyl sulfated-polyacrylamide electrophoresis gels (SDS-PAGE) with 20 μl of pre-stained protein molecular weight marker as standard. The SDS-PAGE separated proteins were electro-transferred to nitrocellulose membranes (Hybond-C pure, Amersham) in transfer buffer containing 25 mM Tris, 193 mM glycine and 20% methanol. The membranes loaded with the proteins were treated with 5% non-fat milk in 0.05% Tween of Tris-buffered saline (TBS-T) at RT for 1 h and then rinsed three times and incubated with anti-AIF or anti-Bit1 antibodies diluted in 0.5% non-fat milk, respectively, at RT for 2 h. The blots were rinsed three times in TBS-T and incubated with a 1:5000 diluted rabbit anti-goat secondary antibody for anti-AIF antibody or a rabbit antichicken secondary antibody for anti-Bit1 antibody conjugated to horseradish peroxidase for 1 h at RT before extensively washed with TBS-T. The blots were developed with ECL reagents (Amersham) according to the manufacturer's instructions and photographed.
Results
Expression of AIF, Bit1, p63 and p53 in EC9706 cells.
Expression of these factors in EC9706 cells were examined with the methods of RT-PCR and Western blot. Both Bit1 and AES expressed at mRNA level were disclosed with RT-PCR (Fig. 1A) . Positive protein expressions of AIF and Bit1 were observed only in the mitochondria of the cells with the INTERNATIONAL JOURNAL OF ONCOLOGY 35: 359-367, 2009 Western blot (Fig. 3B-a) . RT-PCR verified the sub-type of p63 in EC9706 cells is ΔNp63 (Fig. 1B-2 ), but did not reveal any TAp63 expression in these cells (Fig. 1B-1 ). Cells transfected with pcDNA3.1-TAp63Á expressed TAp63Á in mRNA levels (Fig. 1B-4) , while cells transfected with pcDNA3.1 did not express TAp63Á (Fig. 1B-3 ). Before and after pcDNA3.1/ Myc-His-TAp63Á or pcDNA3.1-p53 transfection, a Western blot with protein levels of TAp63Á or p53 was performed. The results showed that cells expressed highly TAp63Á and p53 in protein levels after 24-h transfection, however, they did not express any TAp63Á or expressed p53 at a lower level before transfection (Fig. 1C) .
TAp63Á induces EC9706 cell apoptosis, but cannot be completely blocked by the pan-caspase inhibitor z-VAD-fmk.
Agarose gel electrophoresis revealed a DNA ladder, a typical feature of apoptosis in both the TAp63Á-transfected cells and the p53-transfected cells, but not in the pcDNA3.1-transfected cells (Fig. 2) . DNA fragmentation reached a peak level 24 h after TAp63Á transfection (data not shown), so transfection at 24 h was chosen for all the experiments. TUNEL assay also showed that the number of positive apoptotic cells (239/1500) in TAp63Á-transfection group was much more than that (34/1500) in pcDNA3.1-transfection group (Table I) . To further analyse the relationships between TAp63Á expression and apoptosis, flow cytometry was performed. It was found that the percentages of Annexin Vpositive cells were 1.37% in the negative control (Fig. 6A-a) and 13.64% in the TAp63Á-transfected cells (Fig. 6A-b) . Later stage apoptosis, revealed by both Annexin V and propidium iodide (PI) uptake (upper right panels), was also greater in the TAp63Á-transfected cells compared with that in the negative control (9.63 vs. 4.49%), indicating that expression of TAp63Á induces apoptosis in EC9706 cells.
To study the role of caspase in TAp63Á-induced apoptosis, cells were pretreated with pan-caspase inhibitor z-VAD-fmk (50 μM) 30 min before TAp63Á-transfection. However, it showed only 4.03% of cells with apoptotic changes and 5.12% of cells with later stage apoptosis changes (Fig. 6A-c) , suggesting that TAp63Á-induced apoptosis could be inhibited, but not completely blocked by the pan-caspase inhibitor z-VAD-fmk.
AIF and Bit1 translocation during the process of TAp63Á-induced EC9706 cell apoptosis.
After transfected with pcDNA3.1, pcDNA3.1-TAp63Á or pcDNA3.1-p53 24 h, respectively, the EC9706 cells were harvested. The nucleus, mitochondrial and cytosol fractions were extracted. As loading controls, a nuclear protein (histone), a mitochondrial protein (VDAC) and a cytosol protein (ß-actin) were used to examine the identity and purity of the the subcellular fractions. The results are show in Fig. 3A . Western blot assay to examine the subcellular location of AIF and Bit1 was also performed. AIF, in both nucleus and cytosol proteins, was detected in the cells transfected with either TAp63Á or p53 expression vector, but not in the cells transfected with pcDNA3.1 control (Fig. 3B) . However, Bit1 protein could only be seen in the cytosol, not in the nuclei of the cells transfected with either TAp63Á or p53 expression vector (Fig. 3B ). Either transfected with pcDNA3.1-TAp63Á or with pcDNA3.1-p53, AIF protein became gradually weaker in the mitochondria, and little by little stronger first in the cytosol and then in the nuclei, indicating that AIF protein was first translocated into the cytosol and then the nucleus while Bit1 was only translocated into the cytosol.
Down-regulation of AIF/Bit1 by RNAi can alleviate TAp63Á-induced EC9706 cell apoptosis.
Finally, to identify the relationships between AIF/Bit1 function and TAp63Á-induced cell apoptosis, the EC9706 cells were transfected with recombinant pSilencer AIF-siRNA and pSilencer Bit1-siRNA, respectively. Plain vector was employed as a negative control. The medium containing 400 μg/ml G418 was used and changed every 2 days. Two weeks after transfection, drug-resistant cells were selected and harvested for Western blot assay. AIF and Bit1 protein levels were markedly reduced in the cells transfected with corresponding recombinant pSilencer, while they remained unchanged in the cells transfected with negative plasmid (Fig. 4) , implying that AIF-siRNA and Bit1-siRNA down-regulated AIF and Bit1 protein expression, respectively.
After cells were AIF-siRNA or Bit1-siRNA treated, the cells were transfected with TAp63Á vector. Twenty-four hours later, TUNEL assay and flow cytometry were both performed. In AIF-siRNA treated and TAp63Á transfection group and Bit1-siRNA treated and TAp63Á transfection one, the number of apoptotic cells was 93/1500 and 110/1500, respectively (Table I, Fig. 5 ). Both were less than that of the TAp63Á transfection group, but more than that of the pcDNA3.1 transfection group. Flow cytometry showed that 1.37% of the control group cells were apoptotic, while 13.64% of the TAp63Á transfected cells were apoptotic. However, the AIF-siRNA treated and TAp63Á transfection, cells showed only 4.52% of cells with apoptotic changes (Fig. 6A-d) and the TAp63Á transfected, Bit1-siRNA-treated cells had only 5.72% cells with apotosis ( Fig. 6A-e) , indicating that down-regulation of either AIF or Bit1 alleviates TAp63Á-induced EC9706 cell apoptosis. However, none of these two factors could completely inhibit the TAp63Á-induced cell apoptosis in these cells.
Discussion
p63 protein localization and expression in the basal or progenitor cells of several epithelial tissues such as the epidermis, hair follicles, sweat glands, cervix, tongue, esophagus, mammary glands and prostate (23) (24) (25) . p63 expression is lost as these cells migrate from the basal layer and become terminally differentiated cells. In human esophageal squamous cell carcinoma, however, elevated expression of p63 was ΔNp63, but not TAp63. Expression of ΔNp63 and deficiency of TAp63 may play a significant role Table I . The number of the positive apoptotic cells in different groups. --------------------------------------------------------------------------------------------------- in the development of this disease (26) . Our results also verified the sub-type of p63 in EC9706 cells is ΔNp63 only, not TAp63. It showed that both AIF and Bit1 were located in the cytoplasm of the cells.
We show here that TAp63Á can cause apoptosis through release of AIF and Bit1 from mitochondria in the human esophageal cancer cell line EC9706. Both AIF and Bit1 contain a mitochondrial localization sequence (20, 21) . Under physiological conditions, they are confined to the intermembrane space of mitochondria (19, 20) . Under induction of apoptosis, they are released from mitochondria to participate in apoptotic process in a caspase-independent manner. We monitored cellular distribution of AIF and Bit1 during the TAp63Á-induced apoptosis. However, differences exist. For example, Western blot analysis showed that EC9706 cells tranfected with TAp63Á expression vector resulted in the translocation of AIF from mitochondria to the nucleus via the cytosol. Only in the nucleus, AIF causes peripheral chromatin condensation and large scale DNA fragmentation (20, 27) . Whereas Bit1 is released from mitochondria into cytosol, but not the nucleus, where it forms a complex with AES and promotes apoptosis. It has been shown that AIF translocation in response to p53-induced apoptosis signaling is abrogated in Bax-deficient neurons and transient overexpression of Bax was shown to trigger the release of AIF in 293T and HeLa cells (16) (17) (18) . It has also shown that overexpression of the antiapoptotic family member Bcl-2 prevents the release of AIF (16, 20) . Similarly, cells expressing high levels of Bcl-2 or Bcl-xl may release too little endogenous Bit1 from their mitochondria to form apoptotic levels of Bit1/AES complexes (21) . The mitochondrial localization and the manner of inducing apoptosis are very similar for AIF and Bit1 (28) . Therefore, it would be interesting to know whether cells accept anoikis signals such as loss of attchment and AIF released from mitochondria and whether these two factors cooperate to promote caspase-independent forms of apoptosis. TAp63Á expression causing release of AIF and Bit1 from mitochondria indicates TAp63Á-induced apoptosis triggers the cell-intrinsic pathway. Bcl-2 family proteins whose members have both anti-apoptotic and pro-apoptotic activity have a central role in the control of mitochondria-induced apoptosis (29) . It has been proposed that the Bcl-2 members form channels that facilitate protein transport and interaction with other mitochondrial proteins, and also induce rupture of the outer mitochondrial membrane (30) . Both PUMA and NOXA, which encode the BH3 only domain proapoptotic protein of the Bcl protein family, are recently identified as p53 downstream target genes (10, 31) . Induction of BH3-only Bcl-2 family members may contribute to the Bax translocation. Bax family members, a subfamily of Bcl-2 family proteins, act as tumor suppressors (32, 33) . The presence of either Bax or Bak is essential for apoptosis in many cell types. They contribute to the permeabilization of the outer mitochondrial membrane, allowing efflux of apoptogenic proteins (34) . While they regulate the mitochondrial pathway before caspase activation, the inhibitors of apoptosis proteins (IAP) regulate apoptosis after caspase activation (35) .
In our study, interestingly, both down-regulation of AIF and that of Bit1 can alleviate TAp63Á-induced cell apoptosis, however, neither down-regulation of AIF nor that of Bit1 itself could completely inhibit it. Possibly during the process of TAp63Á-induced apoptosis, other mitochondrial factors such as cyto-c and endonuclease G were released from mitochondria and involved in the initiation of the cellextrinsic apoptotic pathway as well. However, this is a matter of further study.
In summary, we report that TAp63Á can induce human esophageal squamous carcinoma cell apoptosis. It was discovered that AIF was released from mitochondria into nucleus via the cytosol but Bit1 was only released from mitochondria into cytosol. Furthermore, down-regulation of AIF and that of Bit1 by RNAi can alleviate TAp63Á-induced cell apoptosis. Our results inducate that TAp63Á-induced apoptosis can be mediated by AIF and Bit1 released from mitochondria in human esophageal cancer cell line EC9706. Thus, beyond TAp63Á's importance in development and differentiation, we have elucidated that AIF and Bit1, which are both executors of the mitochondrial apoptosis pathway are, at least in part, responsible for the cell death effects of TAp63Á expression in esophageal squamous carcinoma cells.
